Norwegian discovery gives hope for blood cancer patients
Leukemia in adults often has a very poor prognosis. Norwegian researchers have used experiments in mice to develop a treatment that might increase the chance of survival.
Survival is high among children and young people who get leukemia. About nine out of ten who are diagnosed before the age of 44 survive for at least 15 years.
Leukemia has an increasing survival rate, which is due to increased use of chemotherapy and immunotherapy.
But the chance of survival decreases substantially the older you are at the time of diagnosis.
The most common form of leukemia in adults has a very poor prognosis.
Researchers at UiT the Arctic University of Norway have now found a method that can increase survival for this patient group.
The study was recently published in Nature Communications.
Acute myeloid leukemia
Blood cells form and mature in the bone marrow. Acute myeloid leukemia (AML) is a type of acute blood cancer in which the bone marrow becomes overrun with abnormal, immature blood cells. This is because mutations have occurred in the precursors of the blood cells which cause them to grow uncontrollably and not mature properly. They take up the space or inhibit the growth of normal white blood cells. The condition is most common in the elderly.
Around 150 people are diagnosed in Norway each year.
The symptoms of AML can be quite vague, such as lethargy, dizziness, increased tendency to infection and bleeding.
Without treatment, the disease is fatal, but it can be cured with chemotherapy or allogeneic stem cell transplantation.
(Source: Great Norwegian Encyclopedia)
Found signaling substance that counteracts the cancer
Acute myeloid leukemia (AML) is the most common form of leukemia in adults.
“AML is a very aggressive form of cancer. The incidence increases with age and the prognosis is grim,” researcher Lorena Arranz at UiT writes in an email to sciencenorway.no. She is one of the researchers behind the study.
To improve the outlook for this patient group, the researchers had to explore more of the mechanisms behind the disease.
They discovered a substance that fights leukemia. The substance is a kind of soldier that protects against the production of malignant cells.
The researchers found that they can predict who has the worst chance of survival.
Patients who have low levels of this signaling molecule are in a particularly bad situation.
Can boost protective receptors
The UiT researchers were able to increase the levels of this signaling molecule in mice.
The researchers took the naturally occurring signaling substance from humans as their starting point and created a genetic combination, called recombinant DNA, using stem cells.
The signaling substance is a so-called cytokine, called IL-1RN. It is also called an antagonist, which counteracts cancer.
“The mice have been injected with this substance under the skin on several occasions,” Arranz explains in an email to sciencenorway.no.
Gave mice cancer
The mice were also treated with an immunosuppressant drug called Anakinra that is used to reduce inflammation and against autoimmune diseases.
This was done after stem cells from human patients had been transplanted in the mice to bring out the disease in them.
The method was used to test the response to the treatment of the leukemia cells in living tissue, which is a necessary step to take before testing in humans. The leukemia in the mice developed more slowly.
Want to test treatment on humans
This discovery offers hope for this group of leukemia patients. But first the treatment must be tested on humans.
The researchers want to test this on patients in the near future.
“We are now working on trying to select the patients who have the best chance of being helped by this form of therapy,” Arranz writes.
They hope to be able to test the treatment on patients within five to seven years.
This article was amended on 13 January 2022, the paragraph following the sub-heading 'Gave mice cancer' was added.
Translated by Alette Bjordal Gjellesvik.
Villatoro et al., Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation, Nature Communications, 2023. DOI: 10.1038/s41467-022-35700-9